An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients with Prostate Cancer
Sponsor: |
AstraZeneca |
Enrolling: |
Male Patients Only |
IRB Number: |
AAAS6539 |
U.S. Govt. ID: |
NCT04089553 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to find a more effective treatment as well as to gain a better understanding of prostate cancer. This study includes investigational study drugs which are specific for your prostate cancer (module). Treatment in each module will include an investigational medication called AZD4635 as well as another module-specific study drug(s). The combination of AZD4635 and the module-specific drug(s) is expected to stimulate your immune system to help fight your cancer.
This study is closed
Investigator
Emerson Lim, MD
Are you a male of at least 18 years of age? |
Yes |
No |
Do you have prostate cancer? |
Yes |
No |
Have you taken standard of care therapies? |
Yes |
No |
Are you able to perform everyday work independently? |
Yes |
No |